Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

NCT06173284 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

519

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis, Atopic

Interventions

DRUG: 611
DRUG: Matching placebo

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.